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Abstract 
Genetic polymorphisms in the repeat upstream region of the serotonin transporter gene 
(SLC6A4) are associated with individual differences in stress reactivity, vulnerability to 
affective disorders and response to pharmacotherapy. However, the molecular, 
neurodevelopmental and psychopharmacological mechanisms underlying the link between 
SLC6A4 polymorphisms and the emotionally vulnerable phenotype are not fully understood. 
Thus, using the marmoset monkey Callithrix jacchus we characterize here a new 
neurobiological model to help to address these questions. 
We first sequenced the marmoset SLC6A4 promoter and identified a double nucleotide 
polymorphism (-2053AC/CT) and two single nucleotide polymorphisms (-2022C/T and -
1592G/C) within the repeat upstream region. We showed their association with gene 
expression using in vivo quantitative PCR and with affective behavior using a primate test of 
anxiety (human intruder test). The low-expressing haplotype (AC/C/G) was linked with high 
anxiety whilst the high-expressing one (CT/T/C) was associated with an active coping 
strategy in response to threat. Pharmacological challenge with an acute dose of the selective 
serotonin reuptake inhibitor (SSRI), citalopram, revealed a genotype-dependent behavioral 
response. Whilst individuals homozygous for the high anxiety-related haplotype AC/C/G 
exhibited a dose-dependent, anxiogenic response, individuals homozygous for the low 
anxiety-related haplotype CT/T/C showed an opposing, dose-dependent anxiolytic effect. 
These findings provide a novel genetic and behavioral primate model to study the 
molecular, neurodevelopmental and psychopharmacological mechanisms that underlie genetic 
variation-associated complex behaviors, with specific implications for the understanding of 
normal and abnormal serotonin actions and the development of personalized pharmacological 
treatments for psychiatric disorders.  
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Introduction 
Serotonin regulates multiple physiological and behavioral processes crucial for 
emotional homeostasis and survival. Amongst these, the serotoninergic system orchestrates 
the response to threats and its adjustment to specific contexts. However, an exacerbated 
response to uncertain, but non-threatening stimuli can lead to negative adaptive outcomes and 
constitutes one of the core features of anxious behavior (Grupe and Nitschke, 2013). Subjects 
suffering from affective disorders, including anxiety and depression, present alterations in 
serotonin-related functions. Of particular importance is the serotonin transporter, a key 
protein responsible for the reuptake of serotonin from the synaptic cleft and termination of its 
action (Kristensen et al, 2011). 
Genetic polymorphisms in the serotonin transporter gene (SLC6A4) have long been 
associated with individual differences in reactivity to early-life stress and vulnerability to 
affective disorders in humans (Canli and Lesch, 2007; Caspi et al, 2010; Lesch et al, 1996). 
The most studied polymorphism is a variable number of tandem repeats (VNTR) within the 
upstream repeat region, with short alleles being linked to emotionally vulnerable phenotypes 
and reduced SLC6A4 expression, both in humans and macaques (Lesch et al, 1996; Spinelli et 
al, 2007). However, even after taking into account gene x environment interactions (Caspi et 
al, 2003, 2010) and a single nucleotide polymorphism in the human long allele that confers a 
short allele phenotype (Hu et al, 2006), discrepancies exist among these gene-behavioral 
association studies (Munafò and Flint, 2004). Despite these discrepancies, in vitro expression 
analyses have shown that the SLC6A4 repeat region regulates gene expression and that 
genetic variation at this locus has an impact on expression levels (Bennett et al, 2002; Heils et 
al, 1996). 
In addition, correlational imaging studies have shown that even though there are no 
consistent genotype-dependent changes in serotonin transporter binding in the adult brain, 
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there are chemical, structural and functional alterations in neural circuits involved in 
emotional processing in short allele carriers (Jedema et al, 2010; Pacheco et al, 2009; 
Pezawas et al, 2005). Serotonin levels early in life are crucial for the development of the 
central nervous system and the emotional profile in adulthood (Suri et al, 2015). Thus, it has 
been proposed that the short-allele adult phenotype may be the result of changes in neural 
circuitry due to increased serotonin levels during neurodevelopment and the interaction 
between this emotionally vulnerable brain with stressful early life experiences (Ansorge et al, 
2007). 
More recently, large pharmacogenomic studies have shown an interaction between 
SCL6A4 genotype and the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the 
chronic treatment of anxiety and depression, with short-allele carriers presenting a lower 
remission rate (Keers et al, 2011; Serretti et al, 2007). It has also been theorized (Harmer and 
Cowen, 2013) that individual differences in subsequent treatment efficacy may be related to 
an initial anxiogenic effect seen during the early stages of SSRI treatment in various patient 
populations (Kent et al, 1998) and healthy volunteers (Bigos et al, 2008; Browning et al, 
2007; Grillon et al, 2007). However, whether the acute anxiogenic effect of SSRIs is related 
to the SCL6A4 VNTR remains unknown, with few studies having been performed in healthy 
volunteers (Hinkelmann et al, 2010). 
Despite this increasing body of evidence strongly linking polymorphisms within the 
SCL6A4 VNTR with genotype-specific gene regulation, neurodevelopmental changes, 
vulnerability to psychiatric disorders, and response to pharmacotherapy, our understanding of 
the underlying molecular, neurodevelopmental and neuropsychopharmacological mechanisms 
is poor. Hence, it is crucial to characterize an animal model that will allow us to advance our 
understanding of these SLC6A4 polymorphisms and vulnerable phenotypes associations, in 
order to develop effective psychopharmacological treatments. We characterize here such a 
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novel genetic and behavioral model in the common marmoset Callithrix jacchus, a species 
that has gained increasing popularity in molecular neuroscience since the completion of the 
marmoset genome (Flicek et al, 2011) and the generation of the first transgenic marmoset 
(Sasaki et al, 2009). Moreover, given their small size, fast reproductive rate, short 
developmental period and similarity of brain organization with that of humans, marmosets are 
becoming an ideal primate model to study the neurobiological mechanisms underlying 
affective disorders (Sawada et al, 2014).  
In the present study, we characterize the entire marmoset SLC6A4 repeat upstream 
region, identify novel sequence polymorphisms and show their association with both gene 
expression levels and affective responses to threat. In addition, we reveal a variant-dependent 
behavioral response to threat after an acute dose of a SSRI, citalopram. Altogether, these 
findings establish a robust primate model for future molecular and developmental studies of 
the neurobiological mechanisms underlying individual differences in affective behavior, 
vulnerability to affective disorders and pharmacotherapeutic efficacy. 
 
Materials and Methods 
Animals and housing. Common marmosets Callithrix jacchus (age: 29.9±1.2 month, weight: 
433.8±9.1g; see Table S1 for sample size summary) were bred on site at the Innes Marmoset 
Colony (Behavioral and Clinical Neuroscience Institute). Genotyped animals were housed in 
pairs or in families. Animals included in the SLC6A4 gene expression, behavioral and 
pharmacological studies were only housed in pairs. Family relationship information among 
these animals can be found in Figure S1. Temperature (24ºC) and humidity (55%) conditions 
were controlled and a dawn/dusk-like 12h-period was maintained. They were provided with a 
balanced diet and water ad libitum. All procedures were performed in accordance with the 
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project and personal licenses held by the authors under the UK Animals (Scientific 
Procedures) Act 1986. 
Cloning and sequencing of the marmoset SLC6A4 repeat and promoter regions. A 2.4kb-
fragment spanning from -2.3kb to the first exon of the SLC6A4 marmoset gene was cloned 
using a PCR-based strategy. Briefly, the exon 1 and the proximal promoter region were 
amplified using the following primers: SLC6A4-AF, SLC6A4-AR, SLC6A4-BF1, SLC6A4-
BR2, SLC6A4-CF1, SLC6A4-CF2 and SLC6A4-CR (Table S2). HotStarTaq DNA Polymerase 
(Qiagen Ltd., UK) was used in a MJ ResearchTM PTC-200 thermal cycler [conditions: 
activation 16 min at 94 ºC, 50 cycles of 30 sec at 94 ºC, 30 sec at TA1ºC (TA1 = from 54 to 60 
ºC, according to each primer Tm) and 1 min at 72 ºC; and termination 5 min at 72 ºC]. The 
300 bp upstream region of the promoter was cloned using inverse PCR methods with NspI 
and the following primers: IPCR-F1 and IPCR-R1 [conditions: activation 16 min at 94 ºC, 30 
cycles of 30 sec at 94 ºC, 30 sec at TA2ºC (TA2= from 74 to 58 ºC step-down program) and 4 
min at 72 ºC; and termination 5 min at 72 ºC]. The PCR products were cloned using the 
TOPO TA cloning kit system (Invitrogen Ltd., UK). Inserts were sequenced by GeneService 
Ltd (Cambridge) and consensus sequence was annotated in Nucleotide database 
(http://www.ncbi.nlm.nih.gov/nuccore) with the accession number HG515029 (Fig. S2). 
Determination of the SLC6A4 transcription start site. Total RNA was extracted from 
marmoset Raphe nuclei by homogenization with TRI Reagent (Sigma) using the MagNA 
Lyser Instrument (Roche), followed by chloroform extraction and ethanol precipitation. RNA 
pellets were washed in 70% EtOH and resuspended in 50µl of water and stored at -80°C. To 
amplify the 5’ cDNA sequence of marmoset SLC6A4, a system for rapid amplification of 
cDNA ends (5’RACE) was used on total RNA extract using First Choice™ RLM-RACE kit 
(Ambion), following the manufacturer's protocol (see Supplementary Materials and 
Methods and Table S2). 
©    2016 Macmillan Publishers Limited. All rights reserved.
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Repeat region sequence alignment. Marmoset repeats were characterized by multiple 
sequence alignments. Callithrix Jacchus gene sequences were obtained from our own 
SLC6A4 clone sequencing and from the Ensembl database (www.ensembl.org). Human and 
other primate SLC6A4 sequences (Macaca mulatta and Pongo pygmaeus) were obtained from 
Ensembl database. The Gorilla gorilla (accession number AB061805.1) and Saguinus 
oedipus (accession number AB326308.1) were obtained from the NCBI website 
(www.ncbi.nlm.nih.gov/nuccore). To determine the first and last repeats of the marmoset 
region a preliminary alignment was performed with the human, macaque and marmoset 
sequences using Clustal Omega online (http://www.ebi.ac.uk/Tools/msa/clustalo/) (Fig. S3). 
The internal repeats were aligned manually for all primate species based on the Lesch et. al. 
(1997) repeat consensus sequence unit (Fig. S4). 
Genotyping. Blood samples were taken from the femoral vein under sedation (0.1ml i.m., 
Vetalar V 100 mg/ml, Pfizer Ltd., UK). A syringe was prefilled with ACD (acid-citrate-
dextrose: 12.5 g/l Na Citrate, 10 g/l D-glucose, 6.85 g/l Citric Acid) anticoagulant. Genomic 
DNA (gDNA) extraction was performed using Dneasy Blood & Tissue kit (Qiagen Ltd., UK) 
(yield 2-6 µg per sample). Hair follicles were plucked from the animal’s back. Samples were 
processed using the QIAamp DNA Micro kit for forensic casework samples (Qiagen Ltd., 
UK) (yield 0.5-1.2 µg per sample). Primers were designed to flank the SLC6A4 repeat region: 
RPRF and RPRR (Table S2). HotStarTaq Plus DNA Polymerase (Qiagen Ltd., UK) was used 
in a BioRad C1000 thermal cycler (conditions: activation 15 min at 94 ºC; 44 cycles of 30 sec 
at 94 ºC, 30 sec at 55 ºC and 1 min at 72 ºC; and termination 5 min at 72 ºC). The PCR 
product was visualized in an agarose gel, purified using Mini Elute PCR Purification kit 
(Qiagen Ltd., UK) and sent for sequencing (Source BioScience, Cambridge, UK). Primers 
used for sequencing can be found in Table S2. Chimaerism: when studying the behavioral 
and pharmacological effects, which are dependent upon the brain, animals were genotyped 
©    2016 Macmillan Publishers Limited. All rights reserved.
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using hair follicles, which showed the lowest level of chimaerism (Benirschke et al, 1962; 
Sasaki et al, 2009), and the same genotype as the brain (Table S3). When measuring RNA in 
blood, samples were genotyped using genomic DNA extracted from the same blood tissue, 
taking into account the chimaerism. Captive (Bethesa, US) and free-range (Rio Grande do 
Norte, Brazil) populations of marmosets were genotyped using hair follicles (Table S4). 
Expression assay with qPCR. Total RNA was extracted using the QIAamp RNA Blood Mini 
kit (Qiagen Ltd., UK). Samples were stored at -80 ºC till use. cDNA synthesis and real time 
qPCR was performed using Brilliant II SYBR Green QRT-PCR Master Mix Kit, 1-Step 
(Agilent Technologies, UK) using primers spanning SLC6A4 exons 12-13: SLC6A4-F and 
SLC6A4-R (Table S2). Porphobilinogen deaminase gene (PBGD) was used as the reference 
gene using primers spanning exons 13-14: PBGD-F and PBGD-R. All primer combinations 
were designed to span exon-exon boundaries. All reactions were performed in duplicate for 
each individual and controls (conditions: cDNA synthesis 30 min at 50 ºC, activation step 10 
min at 95ºC, 40 two-step cycles of denaturation 30 sec at 95ºC and combined 
annealing/extension 1 min at 60ºC, final melting curves to check specificity of the product) in 
a DNA Engine Opticon 2 thermocycler (MJ Research Inc.). Results were compared with a 
gene-specific standard curve and normalized to the expression of PBGD (van Lelyveld et al, 
2008). Data analysis: results were analyzed with one-way ANOVA followed by LSD post 
hoc contrasts (SPSS Statistics 22.0). Data are presented as mean ± s.e.m. A p<.05 was 
considered statistically significant. 
Human Intruder Test (HIT). Anxious behavior was assessed using the HIT (Agustín-Pavón 
et al, 2012). Marmosets were separated from their cage mate and restricted to the upper right 
hand quadrant of their home cage (separated phase). After 8 min, an unfamiliar person 
entered the room. The intruder stood 40 cm from the front of the cage and stared at the 
marmoset, maintaining eye contact, for 2 min (intruder phase). Marmoset performance was 
©    2016 Macmillan Publishers Limited. All rights reserved.
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recorded with a HD video camera (Genie CCTV-C5351/12, Korea) and a shotgun condenser 
microphone (Pulse-NPM702, Taiwan) with a preamplifier (Pulse-PLS00335, China). Once 
the intruder had left the room, recording went on for 5 min to observe the recovery of normal 
behavior. Several measures were scored off line by an experimenter blind to the genotype 
using the program JWatcher V1.0 (http://www.jwatcher.ucla.edu/): average distance 
(mean of the proportion of time spent in each of fifteen locations with respect to the cage 
front); locomotion (proportion of time spent in translational movements between locations); 
jumps (number of jumps made to the front of the cage, towards the human intruder); bobbing 
event (number of rapid and repetitive side-to-side movements of the upper body while sitting 
and staring at the object of interest); and number of vocalizations (tsik, egg, tsik-egg and tse-
like calls). For more details see Supplementary Materials and Methods and Fig. S5. Data 
analysis: Distance and locomotion were scored and analyzed with repeated measures 
ANOVA for both separated and intruder phases. For the intruder phase, a principal 
component analysis (PCA) was performed on all eight variables, to extract the behavioral 
dimensions underlying the response to threat (Table S5). The PC1 and PC2 derived from the 
PCA corresponded to Anxiety and Coping Strategy, respectively, based on the behavioral 
variable loadings (Agustín-Pavón et al, 2012). A two-way ANOVA was used to compare the 
two component scores (PC1 and PC2) between the SLC6A4 genotypes followed by LSD 
pairwise comparisons. One-way ANOVA (or non-parametric test when normality was not 
achieved) followed by post-hoc pairwise comparisons were also performed for each 
individual variable. All statistical analyses were performed with SPSS Statistics 22.0. Data 
are presented as mean ± s.e.m. A p<.05 was considered statistically significant. 
Pharmacological manipulation on HIT. Twelve homozygous marmosets were included in 
this study (Table S1). Animals were injected i.m. with citalopram (2.5 or 10 mg/kg) or 
vehicle (0.01 M PBS-HCl) 25 minutes before the intruder phase. We selected citalopram as it 
©    2016 Macmillan Publishers Limited. All rights reserved.
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is a commonly used SSRI in the clinic and has been used when studying the impact of 
SLC6A4 VNTR on treatment efficacy (Keers et al, 2011). HIT procedures were exactly the 
same as described above. To avoid habituation to the human intruder across sessions the 
intruder wore different realistic rubber human masks each session (Greyland Film spol. s r.o., 
Czech Republic). The experimental design was a latin square randomized by sex, genotype 
and masks. Treatment order was the same for all individuals (lower dose, higher dose and 
vehicle) with two weeks between each session. Data analysis: to calculate the PCA scores for 
each treatment, the variable values were standardized using the mean and standard deviation 
of the control condition (injection with vehicle) of the experimental subpopulation used in this 
study (N=12). These standardized values were then used in a PCA function derived from the 
previously performed PCA that included the whole population (N=52). PCA scores and 
variables were analyzed using repeated measure ANOVA with one between subject factor 
(haplotype) and one within subject factor (treatment), using SPSS Statistics 22.0. Data are 
presented as mean ± s.e.m. A p<.05 was considered statistically significant. 
 
Results 
 
New sequence polymorphisms in the marmoset SLC6A4 upstream repeat region are 
linked to gene expression levels 
To characterize genetic variation at the marmoset SLC6A4 repeats, we cloned the 
promoter region from -2.3kb to the first exon using a PCR-based method (Table S2) and 
generated a consensus sequence (accession number HG515029) (Fig. S2). Using 5’-RACE 
technique we experimentally identified the marmoset SLC6A4 transcription start site 
(highlighted in Fig. S2) and determined the repeat boundaries by performing a series of 
sequence alignments, revealing the presence of 32 repeats (Fig. S3 and S4). We found no 
©    2016 Macmillan Publishers Limited. All rights reserved.
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variation in the number of tandem repeats in our colony (N=144 animals). Instead, we 
identified sequence polymorphisms: one dinucleotide polymorphism in the 3rd repeat (-
2053AC/CT) and two single nucleotide polymorphisms in the 4th (-2022C/T) and the 23rd (-
1592G/C) repeats (Fig. 1A). The haplotypes AC/C/G and CT/T/C showed high frequencies in 
our colony (49.6 and 42.4%, respectively) while the CT/C/G haplotype was less common 
(8%) and no other combination was detected (Table S1). These haplotypes were also found in 
62 animals from the marmoset colony maintained at the National Institute of Neurological 
Disorders and Stroke (Bethesda, United States) and the AC/C/G and CT/T/C haplotypes were 
also present in 47 individuals from free-ranging marmoset families living at the FLONA of 
Nísia Floresta field station - ICMBio (Rio Grande do Norte, Brazil). Genotypic frequencies of 
these captive and free-ranging populations are provided in Table S4. 
Due to the low frequency of the CT/C/G haplotype and subsequent low number of 
CT/C/G carriers in our colony, we focused our subsequent analysis on the most frequent 
haplotypes, AC/C/G and CT/T/C, the genotypic frequencies of which followed Hardy-
Weinberg equilibrium (X2(1)=3.06) (Table S1). Quantitative PCR studies have shown that 
SLC6A4 mRNA levels in human brain and lymphoblast cultures are similar (Gyawali et al, 
2010) and more recent studies have proposed lymphocytes as an alternative peripheral model 
of central serotonin function (Marazziti et al, 2013). Thus, we assessed differential gene 
expression between SLC6A4 genotypes using marmoset lymphocytes (N=35). Marmosets 
homozygous for the AC/C/G haplotype showed a significant reduction of 25 % in SLC6A4 
gene expression compared with individuals homozygous for the CT/T/C variant, with samples 
from heterozygous marmosets expressing intermediate levels (Fig. 1B). This effect was 
independent of sex or age (Table S6). 
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The marmoset SLC6A4 polymorphisms are associated with anxiety and coping strategy 
in response to threat 
To investigate the contribution of the marmoset SLC6A4 polymorphisms to affective 
behavior, we used the Human Intruder Test (HIT, N=52) (Agustín-Pavón et al, 2012). During 
the intruder phase, the marmosets spent more time at the back of the cage, maintaining some 
distance between them and the unfamiliar person (increased average distance) and moved 
around much less (reduced locomotion) compared to the separated phase (Table 1). The two 
principal components (PC1=anxiety and PC2=coping strategy) derived from the PCA 
explained together over 63% of the total variance (Fig. 2A and Table S5). When comparing 
individual PC scores between genotypes, marmosets homozygous for the low-expressing 
AC/C/G haplotype displayed significantly higher anxiety (higher PC1 scores, Fig. 2B, left) 
and a more passive coping strategy (lower PC2 scores, Fig. 2B, right) than the CT/T/C 
homozygotes, which showed the opposite behavioral pattern. This effect was independent of 
sex or age (Table S6). 
The increased PC1 scores in AC/C/G reflected reduced locomotion, increased distance 
from the intruder, and high numbers of head and body bobbing and alarm calls (Fig. 2A and 
Table 1), which are behaviors corresponding to high anxiety (Agustín-Pavón et al, 2012; 
Carey et al, 1992). In contrast, the increased PC2 scores in CT/T/C homozygous were related 
to high numbers of mobbing vocalizations implicated in active coping in response to stress 
(Bezerra and Souto, 2008; Cross and Rogers, 2006). Videos S1 (for homozygous AC/C/G) 
and S2 (for homozygous CT/T/C) show representative examples of these two distinct 
behavioral phenotypes. 
 
The marmoset SLC6A4 polymorphisms modulate the effect of an acute dose of a 
serotonin reuptake inhibitor on the response to threat 
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To determine whether the marmoset SLC6A4 polymorphisms influence the effect of 
SSRIs on affective responses, we compared HIT performance across homozygous genotypes 
after an acute dose of citalopram (N=12). Neither of the two acute doses of citalopram tested 
had any impact on the behaviors measured during the separated phase (Table S7) nor on the 
PCA factor scores during the intruder phase (Table S8), although PC1 scores were higher 
overall in the AC/C/G compared to the CT/T/C marmosets, replicating our previous finding in 
this subgroup. However, consistent with previous studies showing that distance from the 
human intruder is highly sensitive to anxiolytics (Carey et al, 1992), citalopram had a 
genotype-dependent effect specifically on average distance (Fig. 3A and B). Specifically, 
there was a dose-dependent increase in average distance in high trait anxious AC/C/G 
marmosets, such that they spent more time away from the human intruder at the cage front, 
positioning themselves in the middle of the cage following the low dose (Fig. 3C, middle 
panel) and at the back of the cage following the high dose (Fig. 3C, right panel), indicative 
of heightened anxiety. In contrast, the CT/T/C homozygous marmosets exhibited the opposite 
behavioral pattern, moving closer to the intruder and thus reducing the average distance with 
increasing doses of citalopram, indicative of a reduction in anxiety (Fig. 3D, right panel). 
This effect was independent of sex and age (Table S6). Both genotypes showed reduced 
locomotion and numbers of jumps to the front in response to the acute citalopram (Fig. S6). 
 
Discussion 
 
We report here, a new genetic and behavioral primate model highly relevant for the 
study of the underlying mechanisms of gene-affective behavior associations. We identify 
novel functional sequence polymorphisms within the marmoset SCL6A4 upstream repeat 
region and show their association with individual differences in gene expression and negative 
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affective behavior. In addition, we reveal a genotype-specific behavioral effect of an acute 
dose of the SSRI citalopram, with individuals carrying the low expressing haplotype showing 
a dose-dependent anxiogenic response, in contrast to the anxiolytic response in those carrying 
the high expressing haplotype. 
Genetic variation in the upstream repeat region of the SCL6A4 gene has been 
extensively investigated in both human and non-human primates (Inoue-Murayama et al, 
2000; Lesch et al, 1997). In particular, a recent study in the marmoset showed no variation in 
the number of repeats, however their sequence was incomplete (Pascale et al, 2012). Here, we 
have determined the full length of the marmoset repeat region with a total number of 32 
repeats. Instead of a VNTR, we have identified three sequence polymorphisms within the 
repeat region that parallel the behavioral and gene expression effects associated with the 
human and macaque VNTRs. The importance of sequence variation in this region is 
highlighted by the presence of a single nucleotide polymorphism within the human repeat 
polymorphic region that is also linked to SCL6A4 expression and psychiatric disorders (Hu et 
al, 2006). Moreover, the marmoset sequence polymorphisms reported here showed haplotype-
specific gene expression levels that correspond with the expression changes associated with 
repeat length and sequence polymorphisms using human lymphocyte cell lines (Bennett et al, 
2002; Hu et al, 2006; Lesch et al, 1996). 
Evidence that the haplotypes AC/C/G, CT/T/C and CT/C/G are not restricted to our 
colony is provided by their detection within the marmoset-breeding colony at the National 
Institute of Neurological Disorders and Stroke (Bethesda, United States). The former two 
haplotypes are also present in five free-ranging marmoset families living at the FLONA of 
Nísia Floresta field station - ICMBio (Rio Grande do Norte, Brazil). The failure to detect the 
low frequent CT/C/G haplotype suggests that it may not be present in wild populations. 
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Consistent with reports in humans and macaques that have linked the short alleles 
with emotionally vulnerable phenotypes and anxiety traits, the low-expressing haplotype in 
the marmoset (AC/C/G) was also associated with high anxiety. However, this contrasts with a 
study in macaques which detected no association between the SLC6A4 VNTR and ‘anxious 
temperament’ using a non-eye contact HIT (Oler et al, 2010), although differential neural 
circuitry have been reported (Kalin et al, 2008). One possible explanation may be that the 
macaque and marmoset behavioral models are characterizing distinct trait anxiety phenotypes 
(Shackman et al, 2013; Shiba et al, 2014) that are differentially sensitive to SLC6A4 VNTR. 
This is particularly likely since these primate models measure different behaviors in response 
to the human intruder in two quite distinct contexts, in the home cage in case of the marmoset 
and in a separate isolated room in macaques. 
In this study we have also revealed an effect of the SCL6A4 polymorphism on a 
second dimension of the affective response, namely coping strategy. The high-expressing 
haplotype CT/T/C was associated with an active coping strategy in response to threat. 
Although a role for SLC6A4 variation in coping strategy has not been previously reported, 
differences in passive and active coping styles have been related to altered serotonin release in 
the dorsal raphe nucleus in response to stress (Amat et al, 2005). Moreover, an active coping 
style has been associated with increased aggressive behavior and reduced brain serotonin 
levels (Koolhaas et al, 2010). 
An important question arising from these findings is why a gene-behavioral 
association was revealed in the marmoset, apparently, relatively easily compared to the mixed 
findings in humans? The answer may lie in the more complex phenotype of human, compared 
to marmoset, emotional behavior, that is influenced not only by environmental and genetic 
factors but also a rich life experience. The contribution of genetic variation to individual 
differences in human behavior is thus attenuated by these other influences as well as by 
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compensatory and homeostatic mechanisms. This can be offset, however, by studying such 
behavior in a non-human primate species where the emotional behavior is a less complex 
phenotype and the enormous variation in environment and life experiences between 
individuals can be dramatically reduced by studying a purpose-bred primate colony in a 
controlled environmental setting, as described here. Thus, we would argue for these reasons 
the effects of genotype-behavior relationships have been more easily revealed. In addition, 
when studying emotional behavior it is also important to recognize the variable array of 
responses that are displayed by individual animals to threat. Accordingly, when characterizing 
the repertoire of behaviors that marmosets display in response to a human intruder we took 
into account the ethological behavior of a marmoset when facing predators in the natural 
environment (Ferrari and Ferrari, 1990; Stevenson and Poole, 1976) and under experimental 
conditions (Barros, 2002; Cilia and Piper, 1997). Moreover, by using principal component 
analysis, we were able to reveal the genotype-specific, haplotype dose-dependent effect of 
SLC6A4 genetic variation on two dimensions of the threat response in the marmoset, 
emotionality and coping strategy. 
Nonetheless, the putative contribution of each marmoset polymorphism to gene 
expression and behavior needs to be further investigated using for example, in vitro controlled 
studies in marmoset cell culture (Shimada et al, 2012). In addition, the promoter region 
proximal to the transcription start site should also be explored for genetic variation possibly 
contributing to the phenotypes described here. Finally, we cannot rule out the possibility that 
a different genetic locus, co-segregating with the marmoset SLC6A4 polymorphisms, may be 
also contributing to the genotype-phenotype associations. The development of transgenic and 
genome editing technologies will enable us to confirm these genetic-behavior associations in 
this primate model. 
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In addition to the association with distinct behavioral traits, we showed that the 
marmoset SLC6A4 polymorphisms were also associated with individual differences in the 
response to an SSRI. The AC/C/G high-trait anxious marmosets showed a dose-dependent 
anxiogenic response, as measured by average distance from the anxiety-provoking human. 
This result is of particular interest given a recent report showing increased fear reactivity after 
short term citalopram administration in individuals high in Neuroticism (Di Simplicio et al, 
2014), an anxiety trait dimension associated with the SLC6A4 VNTR in humans (Lesch et al, 
1996). Contrary to this anxiogenic effect, the low-trait anxious CT/T/C marmosets, exhibited 
a reduction in anxiety, i.e. reduced distance from the anxiety-provoking human, in response to 
the acute high dose of citalopram. This latter effect is consistent with the early changes in 
cognitive and neurobiological processing of emotional stimuli detected after short-term SSRI 
administration (Harmer et al, 2006; Murphy et al, 2009) that may account for the later 
improvement of the clinical symptoms observed in long allele carriers. 
Although acute SSRI treatment produced genotype-dependent opposing effects on 
approach-avoidance behavior, its effects on other threat-related measurements were in the 
same direction, i.e. reduction in both locomotion and jumps to the front. However, a reduction 
in the latter behaviors can be brought about by both increases and decreases in anxiety. The 
type of defense response adopted by an animal depends upon the result of the risk assessment 
performed, which takes into account the likelihood and proximity of the threat to determine 
whether to avoid immediately or to approach and gather more information (Blanchard et al, 
2011; McNaughton and Corr, 2004). A high-threat risk assessment of the stimulus results in 
immediate avoidance behavior. In the current study, high anxious AC/C/G animals in 
response to an acute SSRI spent more time at the back of the cage and stayed very still, as 
reflected by reduced locomotion and jumps to the front (Fig. 4). On the contrary, a low-threat 
risk assessment results in approach behavior and increased attention. This was the pattern of 
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behavior observed in the low trait anxious CT/T/C group in response to acute SSRI, resulting 
incidentally in reduced locomotion and jumps to the front as they remained at the front for a 
large percentage of the time attending to the intruder. 
Together, these findings bridge the gap between the finding of reduced responsivity to 
chronic SSRI treatment in short-allele carriers with anxiety disorders (Perna et al, 2005) and 
depression (Keers et al, 2011; Porcelli et al, 2012) and the individual differences in sensitivity 
to the anxiogenic effect of acute SSRIs (Harmer and Cowen, 2013). Currently, there are no 
studies that have specifically considered the relationship between the acute behavioral effects 
of SSRIs and SLC6A4 genotypes with respect to treatment efficacy in patients with mood and 
anxiety disorders. This is an important issue though, since, it is clinical practice to initiate 
SSRI treatment below therapeutic doses if anxiety symptoms are elicited in the early stages of 
treatment. . By demonstrating genome-dependent differential effects of the SLC6A4 
polymorphism on the behavioral effects of acute SSRIs in marmosets, the present study 
provides support for the proposal that individual differences in the acute SSRI-induced 
anxiogenic effect may predict subsequent treatment efficacy (Harmer and Cowen, 2013). 
 
In conclusion, our findings link genetic functional polymorphisms to differential 
SLC6A4 expression and individual differences in complex affective primate behaviors, 
including sensitivity to pharmacotherapies. This new primate genetic model provides a unique 
tool for future investigations into the neurodevelopmental changes and physiological 
endophenotypes associated with serotonin genetic variation that leads to emotional 
vulnerability. Importantly, it also provides a model to study the neurochemical and 
neurobiological mechanisms of SSRI actions and their interactions with serotonin genetic 
variation. Finally, with the recent development of transgenic (Sasaki et al, 2009) and stem cell 
(Shimada et al, 2012) biotechnologies in marmosets, it will be possible in the future to use 
©    2016 Macmillan Publishers Limited. All rights reserved.
Andrea	  M.	  Santangelo	  
	   19	  
this model to further characterize the molecular mechanisms regulating the serotoninergic 
system and develop more efficient and specific molecular therapies for the treatments of 
mood and affective disorders.  
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Table and Figure legends 
 
Table 1| Human intruder test performance summary. Mean±s.e.m. for each variable 
during separated and human intruder phases. 
 
Figure 1| Genetic variation in the repeat upstream region of the marmoset SLC6A4 gene and 
its association with gene expression levels. A) Schematic representation of the marmoset 
SLC6A4 promoter region showing 32 repeats. 3rd, 4th and 23rd repeats containing the double 
and the two single nucleotide polymorphisms, respectively, are shaded in grey. 
Representative examples of electropherograms of the most frequent haplotypes AC/C/G and 
CT/T/C are shown. B) Relative expression values are shown (mean±s.e.m.). One-way 
ANOVA F(2,32)=11.40, p<.001 followed by post hoc LSD: AC/C/G vs CT/T/C p<.001 (***), 
CT/T/C vs AC/C/G&CT/T/C p=.020 (**), AC/C/G vs AC/C/G&CT/T/C p=.047 (*). 
 
Figure 2| The marmoset SLC6A4 polymorphisms are associated with individual differences in 
anxiety and coping strategy, assessed using the human intruder test (HIT). A) Component plot 
in rotated space (variable loadings plot) illustrating the relationship of the individual 
behavioral measures with the two components derived from the principal component analysis 
(PCA). B) Comparison of component behavioral scores (mean±s.e.m.) derived from the PCA 
of the HIT performance. Left panel: Component 1 ‘Anxiety’. Right panel: Component 2 
‘Coping Strategy’. Two-way ANOVA, Genotype x Component interaction F(2,49)=9.36, 
p<.001 (Power 97%), followed by post hoc LSD: AC/C/G vs CT/T/C, Component 1 p=.002 
(**), Component 2, p=.014 (*). 
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Figure 3| SLC6A4 variant-specific anxiety response to an acute dose of a selective serotonin 
reuptake inhibitor, citalopram. Human intruder test (HIT) was used to assess anxiety levels in 
response to vehicle (V) and to a single dose of 2.5 mg/kg (D1) or 10 mg/kg (D2) citalopram, 
25 minutes prior to the intruder phase. A) Schematics of the home cage test quadrant in the 
HIT. High anxiety-related locations are shaded in red (high and rear) and low anxiety-related 
locations are shaded in blue (low and front). B) Average distance. Repeated Measures 
ANOVA, with within factor ‘treatment’ and between factor ‘genotype’. Treatment x genotype 
interaction F(2)=4.214 p=.030; followed by LSD pairwise comparisons. D1: AC/C/G vs 
CT/T/C p=.017; D2: AC/C/G vs CT/T/C p=.012; AC/C/G: V vs D2 p=.012 and CT/T/C: V vs 
D2 p=.031. C-D) Proportion of time spent at different locations (mean±s.e.m.): Front, Middle 
and Back, for each group of homozygous AC/C/G (C) and CT/T/C (D). Two-way repeated 
measures ANOVA with ‘location’ (front, middle, back) and ‘treatment’ (V, D1, D2) as within 
factors and ‘genotype’ as between factor (AC/C/G, CT/T/C). Genotype x treatment x location 
interaction F(4)=6.530 p<.001, followed by LSD post hoc comparisons. (C, middle panel) 
AC/C/G D1: Front vs Middle p=.004; Middle vs Back p=.027. (C, right panel) AC/C/G D2: 
Front vs Back p=.001; Middle vs Back p=.026. (D, right panel) CT/T/C D2: Front vs Back 
p=.040. p<.05 (*); p<.005 (**). 
Figure 4| Schematic depicting the response to threat during the human intruder anxiety test. 
The graph indicates the probability of engaging in different behaviors in relation to the 
perceived intensity of threat. The normal range population described by our principal 
component analysis is shaded in gray. The AC/C/G group perceive the human intruder as a 
relatively high threat, showing high numbers of bobbing events, reduced locomotion and 
jumps, and primarily avoidance of the threat (larger distance from the human intruder). The 
CT/T/C group perceive the human intruder as a lower threat, showing fewer numbers of 
bobbing events, increased locomotion and jumps, and approach behavior to the threat 
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(reduced distance from the human intruder). Acute SSRI in the AC/C/G group produces an 
anxiogenic effect with avoidance of the threat and further reduction in locomotion, jumps and 
numbers of bobbing events, leading to an anxious state of stillness. In contrast, acute SSRI in 
the CT/T/C group induce an anxiolytic effect leading to increased approach behavior, with a 
concomitant reduction in locomotion and jumps, and increased inspection of the human 
intruder (risk assessment). 
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 Table 1| Human Intruder Test performance summary 
 SLC6A4 Genotypes 
 AC/C/G 
homozygous 
AC/C/G&CT/T/C 
heterozygous 
CT/T/C 
homozygous 
Separated phase    
Locomotion (s) a 10.04±1.75 13.44±2.45 17.66±2.53 
Distance (cm) b 71.00±4.06 68.00±4.45 64.34±4.62 
Intruder phase    
Locomotion (s) a 5.88±0.91 c 8.17±2.05 13.27±2.43 
Distance (cm) b 87.75±2.56 81.57±4.98 75.13±4.46 
Bobbing 54.00±5.43 d 31.00±5.80 25.37±5.20 
Jumps 0.90±0.25 1.44±0.62 2.31±0.72 
Egg calls 21.55±3.31 e 11.87±2.95 8.94±2.46 
Tse-like calls 8.35±2.62 12.37±4.70 4.31±1.04 
Tsik calls 0.65±0.36 f 3.67±1.54 6.87±2.59 
Tsik-Egg calls 13.35±3.69 10.94±3.78 17.50±6.00 
 
a Repeated measures ANOVA, Square root transformed, separated vs test phases, 
significant main effect F(1,49)=10.10 p=.003. 
b Repeated measures ANOVA, Square transformed, separated vs test phases, significant 
main effect F(1,49)=36.41 p=.000. 
c ANOVA, Square root transformed, F(2,49)=4.20, p=.021 followed by post hoc LSD: AC/C/G 
vs CT/T/C p=.008, Heterozygous vs CT/T/C p=.036. 
d ANOVA, F(2,49)=8.03 p=.001 followed by post hoc LSD: AC/C/G vs Heterozygous p=.004, 
AC/C/G vs CT/T/C p=.001. 
e ANOVA, Square root transformed, F(2,49)=5.95 p=.005 followed by post hoc LSD: AC/C/G 
vs Heterozygous p=.013, AC/C/G vs CT/T/C p=.002. 
f Kruskal-Wallis X2(2)=10.46, p=.005 followed by Mann-Whitney AC/C/G vs CT/T/C (sig. 2-
tailed) p=.001. 
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